Drug Approval | October 09, 2023
Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films
Subscribe To Our Newsletter & Stay Updated
